Table 4.
Joint space width loss and cartilage volume loss at 36 months in the placebo group according to the co-localization of meniscal extrusion and bone marrow lesions in the medial compartment at baseline
| Ext- (n = 86) | Ext+ (n = 26) | P -value | ||||
|---|---|---|---|---|---|---|
| Joint space width loss | ||||||
| mm | -0.35 ± 0.61 | -0.76 ± 0.67 | 0.002 | |||
| % | -10.36 ± 20.10 | -23.24 ± 19.23 | 0.0008 | |||
| MRI (%) | ||||||
| Global knee | -6.70 ± 2.78 | -8.02 ± 3.28 | 0.034 | |||
| Femur | -6.15 ± 3.29 | -7.28 ± 2.91 | 0.171 | |||
| Plateau | -7.80 ± 5.05 | -10.01 ± 5.79 | 0.005 | |||
| Medial compartment | -7.60 ± 4.63 | -10.40 ± 4.23 | 0.0005 | |||
| Medial femur | -7.90 ± 4.76 | -10.89 ± 3.19 | 0.0002 | |||
| Medial plateau | -6.77 ± 7.52 | -9.07 ± 8.74 | 0.012 | |||
| BML- (n = 68) | BML+ (n = 18) | P -value | BML- (n = 14) | BML+ (n = 12) | P -value | |
| Joint space width loss | ||||||
| mm | -0.23 ± 0.55 | -0.77 ± 0.68 | 0.003 | -0.88 ± 0.82 | -0.61 ± 0.43 | 0.455 |
| % | -5.79 ± 15.35 | -27.64 ± 26.29 | 0.002 | -25.44 ± 22.79 | -20.68 ± 14.62 | 0.589 |
| MRI (%) | ||||||
| Global knee | -6.75 ± 2.81 | -6.50 ± 2.71 | 0.227 | -6.89 ± 3.70 | -9.33 ± 2.19 | 0.066 |
| Femur | -6.39 ± 3.36 | -5.26 ± 2.92 | 0.020 | -6.16 ± 2.97 | -8.57 ± 2.32 | 0.028 |
| Plateau | -7.38 ± 4.15 | -9.40 ± 7.49 | 0.162 | -8.67 ± 7.12 | -11.57 ± 3.37 | 0.093 |
| Medial compartment | -7.08 ± 4.33 | -9.57 ± 5.29 | 0.090 | -9.69 ± 5.50 | -11.22 ± 1.90 | 0.103 |
| Medial femur | -7.54 ± 4.90 | -9.26 ± 4.03 | 0.055 | -10.72 ± 4.08 | -11.08 ± 1.86 | 0.339 |
| Medial plateau | -5.79 ± 5.68 | -10.46 ± 11.70 | 0.185 | -7.04 ± 10.97 | -11.45 ± 4.47 | 0.155 |
Results for cartilage volume loss are percentage (%) of change expressed as mean ± SD. P-values were assessed using the Kruskal-Wallis test. Statistically significant P-values are in bold. Ext, meniscal extrusion; n, number of participants; MRI, magnetic resonance imaging; BML, bone marrow lesions.